Delayed hypersensitivity to 5-fluorouracil associated with reduced dihydropyrimidine dehydrogenase (DPD) activity

Advances in Experimental Medicine and Biology

Volumn 431, Issue , 1998, Pages 147-150

  Duley, John A ^a   Nethersell, Anthony B W ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

AGED; CASE REPORT; CONFERENCE PAPER; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; HETEROZYGOSITY; HUMAN; LYMPHOCYTE; MALE; PRIORITY JOURNAL;

EID: 0031861795     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5381-6_28     Document Type: Conference Paper

References (13)

1. Diasio RB, Beavers TL, Carpenter JT (1988). Familial Deficiency of Dihydropyrimidine Dehydrogenase. J. Clin.Invest. 81:47-51.
2. Zhang R, Lu Z, Lu T, Soong S-J, Diasio RB (1993). Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes. Cancer Research 53:2816-22.
3. Bakkeren JAJM, De Abreu RA, Sengers RCA, Gabreels FJM, Maas JM, Renier WO (1984). Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine in a child with dihydrothymine dehydrogenase deficiency. Clin. Chim. Acta 140: 247-56.
4. Simmonds HA, Duley JA, Davies PM (1990). Analysis of purines and pyrimidines in blood, urine and other physiological fluids. In: Techniques in Diagnostic Human Biochem̀ical Genetics, Wiley-Liss, NY, pp397-424.
5. Lowry OH, Rosebrough NJ, Farr A, Randall RJ (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-75.
6. Henderson MJ, Jones S, Walker P, Duley JA, Simmonds HA (1995). Heterogeneity of symptomatology in two male siblings with thymine uraciluria. J. Inher. Metab. Dis. 18:85-6.
7. Lu Z, Zhang R, Diasio RB (1993). Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver. Cancer Res. 53:5433-8.
8. Harris BE, Carpenter JT, Diasio RB (1991). Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 68: 499-501.
9. Gonzalez FJ, Fernandez-Salguero P (1995). Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. TiPS 16:325-7.
10. Van Gennip AH, Abeling AH, Stroomer NGGM, Van Lenthe H, Bakker HD (1994). Clinical and biochemical findings in six patients with pyrimidine degradation defects. J. Inherited Metabolic Diseases 17:130-2.
11. Webster DR, Becroft DM, Suttle DP (1995). Hereditary orotic aciduria and other disorders of pyrimidine metabolism. In: The Metabolic and Molecular Bases of Inherited Disease, ed. CR Scriver, AL Beaudet, WS Sly, D Valle, chapter 55, McGraw-Hill, NY, pp 1799-1837.
12. Milano G, Etienne M-C (1994) Potential importance of dihydropyrimidine dehydrogenase in cancer chemotherapy. Pharmacogen. 4:301-6.
13. Yokota H, Fernandez-Salguero P, Furuya H, Lin K, McBride OW, Podschun B, Schnackerz KD, Gonzalez FJ (1994). cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J. Biol. Chem. 269:23192-6.